Advanced Glycations End Products in the Skin as Biomarkers of Cardiovascular Risk in Type 2 Diabetes

International Journal of Molecular Sciences

Olga Simó-Servat¹  Alejandra Planas¹  Cristina Hernández¹  Rafael Simó¹ 

[1] Diabetes and Metabolism Research Unit, Vall d’Hebron Research Institute (VHIR), Vall d’Hebron University Hospital, Autonomous University of Barcelona, 08035 Barcelona, Spain;

关键词: cardiovascular disease;    advanced glycation end products;    diabetic retinopathy;    cardiovascular disease biomarkers;    type 2 diabetes;    diabetic complications;   

DOI  :  10.3390/ijms23116234

来源: DOAJ

【 摘 要 】

The incidence and prevalence of diabetes are increasing worldwide, and cardiovascular disease (CVD) is the leading cause of death among subjects with type 2 diabetes (T2D). The assessment and stratification of cardiovascular risk in subjects with T2D is a challenge. Advanced glycation end products are heterogeneous molecules produced by non-enzymatic glycation of proteins, lipids, or nucleic acids. Accumulation of advanced glycation end products is increased in subjects with T2D and is considered to be one of the major pathogenic mechanism in developing complications in diabetes. Skin AGEs could be assessed by skin autofluorescence. This method has been validated and related to the presence of micro and macroangiopathy in individuals with type 2 diabetes. In this context, the aim of this review is to critically summarize current knowledge and scientific evidence on the relationship between skin AGEs and CVD in subjects with type 2 diabetes, with a brief reference to other diabetes-related complications.

【 授权许可】

Unknown